Paper Details

  1. Home
  2. Paper Details

A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years.

Author: ChiuCheng-Hsun, DecreuxAnnabelle, DubinGary, FolschweillerNicolas, HuangLi-Min, KarkadaNaveen, LinLan, PanzerFalko, PonceletSylviane, SchwarzTino F, StruyfFrank, ValenciaAlejandra

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Three doses of the AS04-adjuvanted HPV-16/18 L1 virus-like particle (VLP) vaccine induced high and sustained antibody response against HPV-16, 18, 31, and 45 in girls aged 10-14 years for 10 years, with no serious adverse events or abnormal pregnancy outcomes.
Paper Details　
Original Abstract of the Article :
This study assessed long-term immunogenicity and safety following 3 doses of AS04-adjuvanted human papillomavirus (HPV)-16/18 L1 virus-like particle (VLP) vaccine in females 10-14 years old. Girls included in the immunogenicity subset in the primary controlled, observer-blinded, randomized study (NC...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746471/

データ提供：米国国立医学図書館（NLM）

The Longevity of HPV Vaccine Protection: A Decade-Long Oasis

The journey to prevent cervical cancer, a serious health concern for women, has been long and arduous. Vaccines, like the AS04-adjuvanted human papillomavirus (HPV)-16/18 L1 virus-like particle (VLP) vaccine, offer a promising path to protection. This study, like a desert oasis, examined the long-term effectiveness of this vaccine in adolescent girls. The researchers followed a group of girls who received three doses of the vaccine 10 years after their initial vaccination, evaluating their antibody levels against various HPV strains.

Long-Lasting Protection: A Ten-Year Desert Oasis of Immunity

The results, like a refreshing spring in a parched desert, showed that the vaccine provided sustained protection against HPV-16 and HPV-18, the two strains targeted by the vaccine. This protection was evident even a decade after the initial vaccination. Furthermore, the vaccine also induced antibody responses against other HPV strains, providing broader protection against cervical cancer.

Staying Protected: A Wise Traveler's Approach

This research offers reassurance to those who have received the HPV vaccine. The findings suggest that the protection provided by the vaccine is long-lasting, offering hope for a future free from cervical cancer. It's important to remember, however, that vaccinations are only one aspect of preventative care. Maintaining healthy habits, like regular checkups and safe sexual practices, is crucial for overall health.

Dr.Camel's Conclusion

This study provides a beacon of hope in the fight against cervical cancer. The long-lasting protection offered by the HPV vaccine is a testament to the power of science and the importance of vaccination. Like a desert oasis, this research provides a refuge of protection against a serious threat to women's health.

Date :
  1. Date Completed 2020-03-02
  2. Date Revised 2020-03-09
Further Info :

Pubmed ID

31268383

DOI: Digital Object Identifier

PMC6746471

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.